These are prior Capital Midwest Fund (CMF) investments that are not representative of CMF's strategy going forward. CMF no longer invests in pre-clinical or clinical-stage companies.
IPO - Exited Position
Gemphire Therapeutics was a clinical-stage biopharmaceutical company focused on cardiometabolic disorders, including dyslipidemia and NASH. In December 2019, Gemphire Therapeutics merged with NeuroBo Pharmaceuticals (NASDAQ: NRBO), which is the surviving entity.
Ocuphire Pharma is a clinical-stage biopharmaceutical company focused on a variety of ophthalmic disorders. The company's lead drug candidate is a once-daily eye drop, Nyxol®, to treat multiple front-of-the-eye disorders, including night vision disturbances, pharmacologically-induced mydriasis, and presbyopia.
Rapid Diagnostek developed a patented, point-of-care, biosensor-based platform appropriate for detecting proteins, bacteria, viruses, and other substances contained in liquid samples. Rapid Diagnostek was acquired by Qorvo in 2016.
IPO - Acquired
Sierra Oncology is a biotechnology company developing therapeutics for the treatment of hematology and oncology.
TPI focused on making biosimilar medications affordable by developing a proprietary, single-use technology platform, MayaBio®, to build a strong pipeline of biosimilar candidates. TPI renamed to Adello Biologics in 2016 and was acquired by Kashiv BioSciences in 2019.
10556 N Port Washington Rd
Mequon, WI 53092